-

New Cation Trap Column Workflow Improves Uptime for Anionic Contaminants Testing of Industrial Waters

The Thermo Scientific Dionex CR-CTC III application workflow offers cost-efficient trace-level analysis

SUNNYVALE, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, now offers nuclear power plants a new continuously regenerated cation trap column (CR-CTC) application workflow for robust and efficient trace anion contaminant testing of industrial waters.

The new Thermo Scientific Dionex CR-CTC III application workflow offers a solution to reduce the high cost and complexity of anion analysis in lithium borated water, and boiler and cooling water, in nuclear power plants. The workflow comprises the Thermo Scientific Dionex ICS-6000 capillary HPIC System or Thermo Scientific Dionex Integrion HPIC System and the Thermo Scientific Dionex IonPac AS28-Fast-4µm column, and allows for the determination of sub-µg/L anionic contaminants, utilizing a new single-step injection method of cation matrix elimination.

“This latest CR-CTC workflow aims to help reduce plant maintenance costs by minimizing plant and equipment corrosion through comprehensive trace anion contaminant analysis of industrial waters,” said Dino Alfano, vice president and general manager, ion chromatography and sample preparation, Thermo Fisher Scientific. “The new workflow provides optimum performance for nuclear power application requirements, such as removing lithium in borated waters by employing 100% carboxylate resin, and avoiding labile sulfonate that can end up in the cooling water as a corrosive anion.”

The new workflow offers a user-friendly experience, reducing the time required for training, and a single-step injection method of cation matrix elimination to increase productivity. The lower cost of ownership and maximized operational uptime help meet the ongoing increased energy demand.

Learn more about the new Thermo Scientific CR-CTC III application workflow.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The new Thermo Scientific Dionex CR-CTC III application workflow offers a solution to reduce the high cost and complexity of anion analysis.
Release Versions

Contacts

Media:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

More News From Thermo Fisher

Thermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher’s PPD™ clinical research business will gain enterprise-level access to HealthVerity’s TaXOnomy® claims dataset, representing more than 270 million de-identified pa...

Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE-SG100K study, one of the region’s most ambitious and diverse population-scale biobank initiatives. The collaboration reflects growing investments from national population studies looking to harness proteomics to drive insight into real-time disease biology for applicat...

Thermo Fisher Scientific Introduces the Gibco™ CTS™ Compleo™ Fill and Finish System to Help Streamline Cell Therapy Manufacturing

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the global launch of the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated, functionally closed solution designed to streamline formulation and filling in cell therapy manufacturing. Because cell therapies often begin with patient-derived cells, manufacturing workflows must accommodate variability in cell count, concentration and viability. As more therapies move toward c...
Back to Newsroom